Applied Therapeutics to Present at the UBS Global Healthcare Conference

Rhea-AI Summary

Applied Therapeutics, Inc. (Nasdaq: APLT) is participating in a fireside chat at the UBS Global Healthcare Conference on March 25, 2022, at 10:45 a.m. ET, in New York. The event can be accessed via webcast on their Investor Relations page, with a replay available post-event. The company specializes in developing novel biopharmaceutical candidates targeting significant unmet medical needs, including CNS rare metabolic diseases and diabetic cardiomyopathy. Their leading drug candidates include AT-007 and AT-001, among others.

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, March 25, 2022 at 10:45 a.m. ET in New York.

Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Contacts

Investors:
Maeve Conneighton
(212) 600-1902 or
appliedtherapeutics@argotpartners.com

Media:
media@appliedtherapeutics.com

FAQ

When is Applied Therapeutics participating in the UBS Global Healthcare Conference?

Applied Therapeutics is participating in the UBS Global Healthcare Conference on March 25, 2022, at 10:45 a.m. ET.

Where can I access the webcast for the UBS Global Healthcare Conference?

The webcast for the UBS Global Healthcare Conference can be accessed on the Events page under the Investor Relations section of the Applied Therapeutics website.

What are the lead drug candidates of Applied Therapeutics?

The lead drug candidates of Applied Therapeutics include AT-007 for CNS rare metabolic diseases and AT-001 for diabetic cardiomyopathy.

What is the stock symbol for Applied Therapeutics?

The stock symbol for Applied Therapeutics is APLT.

What is the focus of Applied Therapeutics's drug development?

Applied Therapeutics focuses on developing novel drug candidates for high unmet medical needs, particularly in CNS rare metabolic diseases and diabetic cardiomyopathy.